Ftse Mib
33.766,29
-0,06%
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
NASDAQ
19.572,60
1,03%
Bitcoin
95.446,90
-1,81%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ IceCure Medical Ltd (ICCM) IceCure Medical Ltd (ICCM) Notizie

ICCM

IceCure Medical (ICCM)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ICCM
DataOraFonteTitoloSimboloCompagnia
16/12/202414:30PR Newswire (US)Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual MeetingNASDAQ:ICCMIceCure Medical Ltd
05/12/202414:35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ICCMIceCure Medical Ltd
05/12/202414:30PR Newswire (US)IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study ResultsNASDAQ:ICCMIceCure Medical Ltd
26/11/202414:30PR Newswire (US)IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® CryoablationNASDAQ:ICCMIceCure Medical Ltd
25/11/202414:30PR Newswire (US)IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent OfficeNASDAQ:ICCMIceCure Medical Ltd
20/11/202414:30PR Newswire (US)IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024NASDAQ:ICCMIceCure Medical Ltd
19/11/202414:30PR Newswire (US)IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of HealthNASDAQ:ICCMIceCure Medical Ltd
15/11/202403:38Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ICCMIceCure Medical Ltd
08/11/202416:05Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:ICCMIceCure Medical Ltd
08/11/202413:00PR Newswire (US)FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast CancerNASDAQ:ICCMIceCure Medical Ltd
29/10/202413:30PR Newswire (US)Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from StakeholdersNASDAQ:ICCMIceCure Medical Ltd
21/10/202414:30PR Newswire (US)IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation SystemNASDAQ:ICCMIceCure Medical Ltd
15/10/202422:22Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:ICCMIceCure Medical Ltd
07/10/202414:15PR Newswire (US)IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging ConferenceNASDAQ:ICCMIceCure Medical Ltd
24/09/202414:15PR Newswire (US)IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free RateNASDAQ:ICCMIceCure Medical Ltd
16/09/202414:00PR Newswire (US)Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft TissuesNASDAQ:ICCMIceCure Medical Ltd
12/09/202414:00PR Newswire (US)IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024NASDAQ:ICCMIceCure Medical Ltd
04/09/202414:30PR Newswire (US)IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets ConferencesNASDAQ:ICCMIceCure Medical Ltd
28/08/202414:30PR Newswire (US)USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation TechnologiesNASDAQ:ICCMIceCure Medical Ltd
20/08/202414:30PR Newswire (US)IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global MarketsNASDAQ:ICCMIceCure Medical Ltd
16/08/202414:00Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ICCMIceCure Medical Ltd
14/08/202414:30PR Newswire (US)IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of SurgeryNASDAQ:ICCMIceCure Medical Ltd
13/08/202414:30PR Newswire (US)IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024NASDAQ:ICCMIceCure Medical Ltd
07/08/202414:30PR Newswire (US)IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials"NASDAQ:ICCMIceCure Medical Ltd
22/07/202414:30PR Newswire (US)99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer SocietyNASDAQ:ICCMIceCure Medical Ltd
19/07/202422:30PR Newswire (US)IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price NotificationNASDAQ:ICCMIceCure Medical Ltd
09/07/202414:30PR Newswire (US)European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast CancerNASDAQ:ICCMIceCure Medical Ltd
01/07/202414:30PR Newswire (US)U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbesNASDAQ:ICCMIceCure Medical Ltd
18/06/202414:30PR Newswire (US)IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024NASDAQ:ICCMIceCure Medical Ltd
12/06/202414:30PR Newswire (US)Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal FunctionNASDAQ:ICCMIceCure Medical Ltd
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ICCM

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENI
Eni
BIT
STLAM
Stellantis NV
BIT
SPM
Saipem
BIT
ENEL
Enel
BIT
TIT
Telecom Italia
BIT
RACE
Ferrari NV
BIT
STMMI
ST Microelectronics
BIT
BAMI
Banco BPM
BIT
BPE
Bper Banca
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
PRY
Prysmian
BIT
TEN
Tenaris
BIT
MONC
Moncler
BIT
FBK
Finecobank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network